Fulgent Genetics (NASDAQ:FLGT) Updates FY 2026 Earnings Guidance

Posted by Geri Gentry on Aug 1st, 2026

Fulgent Genetics (NASDAQ:FLGT – Get Free Report) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of -2.350–2.220 for the period, compared to the consensus earnings per share estimate of -1.820. The company issued revenue guidance of $330.0 million-$340.0 million, compared to the consensus revenue estimate of $351.2 million.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on FLGT. Piper Sandler reissued a “neutral” rating and set a $15.00 price objective (down from $30.00) on shares of Fulgent Genetics in a research report on Tuesday, May 5th. Wall Street Zen raised Fulgent Genetics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 30th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Fulgent Genetics in a research note on Monday, July 6th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $27.00.

Read Our Latest Report on FLGT

Fulgent Genetics Stock Down 18.1%

Shares of Fulgent Genetics stock opened at $16.55 on Friday. The company has a market cap of $470.04 million, a PE ratio of -5.87 and a beta of 0.89. Fulgent Genetics has a 52 week low of $13.46 and a 52 week high of $31.04. The business has a 50 day moving average price of $19.31 and a 200-day moving average price of $19.25.

Fulgent Genetics (NASDAQ:FLGT – Get Free Report) last announced its earnings results on Thursday, July 30th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.12). Fulgent Genetics had a negative net margin of 26.05% and a negative return on equity of 4.82%. The company had revenue of $85.39 million for the quarter, compared to analysts’ expectations of $94.00 million. Fulgent Genetics has set its FY 2026 guidance at -2.350–2.220 EPS. As a group, research analysts anticipate that Fulgent Genetics will post -2.81 EPS for the current year.

Insider Buying and Selling at Fulgent Genetics

In other Fulgent Genetics news, insider Hanlin Gao sold 1,688 shares of Fulgent Genetics stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $17.89, for a total transaction of $30,198.32. Following the transaction, the insider directly owned 990,374 shares of the company’s stock, valued at $17,717,790.86. The trade was a 0.17% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Jian Xie sold 2,146 shares of the company’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $17.89, for a total transaction of $38,391.94. Following the completion of the sale, the chief operating officer owned 367,605 shares of the company’s stock, valued at approximately $6,576,453.45. The trade was a 0.58% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 5,980 shares of company stock worth $106,360. Company insiders own 36.18% of the company’s stock.

Fulgent Genetics News Roundup

Here are the key news stories impacting Fulgent Genetics this week:

Positive Sentiment: Second-quarter revenue rose 4.4% year over year to $85.4 million, supported by Fulgent’s laboratory services and therapeutic development businesses. The company also reported approximately $6.9 million in government award payments over the past year, primarily related to genetic testing services for the Veterans Health Administration. Fulgent Reports Second Quarter 2026 Financial Results
Neutral Sentiment: Institutional positioning was mixed in the latest reported quarter, with 68 investors adding FLGT shares and 92 reducing holdings. Recent government contracts and portfolio changes may provide longer-term signals but are less important to the immediate earnings reaction. Fulgent Genetics Q2 2026 Earnings
Negative Sentiment: Fulgent reported a non-GAAP loss of $0.58 per share, versus the $0.46 loss analysts expected, while revenue of $85.4 million missed the $94.0 million consensus estimate. On a GAAP basis, the net loss was $29.5 million, or $1.05 per share, compared with a profit a year earlier. Fulgent Genetics Reports Q2 Loss, Misses Revenue Estimates
Negative Sentiment: Profitability and cash generation deteriorated: gross profit fell to $25.7 million, operating loss widened to $36.1 million, operating cash flow was negative $23.8 million, and cash and equivalents declined to $26.3 million. Fulgent Genetics Q2 2026 Earnings
Negative Sentiment: Management lowered fiscal 2026 guidance to revenue of $330 million-$340 million, below the $351.2 million consensus, and EPS of negative $2.35 to negative $2.22, worse than the expected negative $1.82. The weaker outlook reinforces concerns about sustained losses and margin pressure. Fulgent Genetics Q2 2026 Earnings Call Transcript

Institutional Investors Weigh In On Fulgent Genetics

A number of institutional investors have recently added to or reduced their stakes in the company. Kestra Advisory Services LLC bought a new position in shares of Fulgent Genetics during the 4th quarter worth approximately $35,000. Raymond James Financial Inc. bought a new position in shares of Fulgent Genetics in the second quarter valued at approximately $49,000. Quantbot Technologies LP purchased a new stake in shares of Fulgent Genetics during the third quarter valued at approximately $61,000. Los Angeles Capital Management LLC purchased a new stake in shares of Fulgent Genetics during the fourth quarter valued at approximately $218,000. Finally, Advisors Asset Management Inc. lifted its holdings in Fulgent Genetics by 2,205.7% during the fourth quarter. Advisors Asset Management Inc. now owns 8,485 shares of the company’s stock worth $223,000 after acquiring an additional 8,117 shares during the period. 48.06% of the stock is owned by institutional investors.

Fulgent Genetics Company Profile

(Get Free Report)

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.